ncRNA basic information ncRNA ID: MI0001729 ncRNA Database: miRBase ncRNA Name: miR-451 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: YWHAZ ncRNA Pathway: Beta-catenin signaling pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Drug Name: Paclitaxel Drug Method: In this study, we aimed to investigate the biological role and molecular mechanisms of miR-451 in drug resistance in breast cancer cell lines and in xenograft model. We show that miR-451 is decreased in human breast cancer specimens and in paclitaxel-resistant (PR) cells. Ectopic expression of miR-451 could inhibit the cell migration and invasion, promoted apoptosis, induced cell-cycle arrest Furthermore, tyrosine3-monooxygenase/tryptophan5-monooxygenase activation protein zeta (YWHAZ) was identified as a direct target of miR-451. Remarkably, the expression of YWHAZ is inversely correlated with the level of miR-451 in human breast cancer samples. Co-treatment with miR-451 mimics and YWHAZ-siRNA significantly enhanced YWHAZ knockdown in both SKBR3/PR and MCF-7/PR cells Moreover, miR-451 markedly inhibited expression of Beta-catenin via YWHAZ and subsequently inhibited downstream gene cyclin D1, c-Myc expression. The results of xenograft model in vivo showed that intratumor injection of miR-451 agomir induced a tumor-suppressive effect in SKBR3/PR drug-resistant xenograft model. Taken together, our findings suggested that miR-451 might be considered as important and potential target in paclitaxel-resistant breast cancer treatment. Drug Response: sensitive

Cancer basic information Cancer: breast cancer Tissue/Cell: cell line (MCF-7, SKBR3, MCF-7/PR and SKBR3/PR)

Other information Title: Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Journal: Cell Death Dis Published: 2017 PubMed ID: 28981108